Haisco Pharmaceutical receives trial approval for HSK41959

Haisco Pharmaceutical Group (SZSE:002653) announced that its subsidiary, Shanghai Haisco Noah Pharmaceutical Technology, has received the "Drug Clinical Trial Approval Notice" for its innovative drug, HSK41959 tablets. The drug, a novel oral small molecule inhibitor, is intended for the treatment of advanced solid tumors. The NMPA accepted the clinical trial application in January 2025 and has now granted permission for clinical trials, classifying HSK41959 as a Category 1 chemical drug. Preclinical studies have demonstrated the drug's ability to inhibit tumor cell proliferation with good tolerability. Haisco cautions that drug development involves risks and uncertainties.